ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.

Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).

FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical trials evaluating finerenone, a mineralocorticoid receptor antagonist (MRA). The study aimed to assess finerenone's impact on cardiovascular and renal outcomes in a diverse patient population of over 19,000 individuals with varying degrees of heart failure, chronic kidney disease, and type 2 diabetes.

Evidence shows that finerenone could be useful in broad, high-risk patient populations with overlapping cardio-kidney-metabolic conditions. 

Interview Questions:

1. What is the importance of the study?
2. What is the study design, patient cohort and outcome measures?
3. What are the key findings?
4. Were there any unexpected or surprising findings?
5. What are the take-home messages?
6. What are the next steps?

Recorded on-site at ESC Congress 2024, London.  

Editors: Jordan Rance and Mirjam Boros. 
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.  

Support: This is an independent interview produced by Radcliffe Cardiology.